Utility of PET-MRI in Surveillance of Paediatric Brain Tumours
PET-MRI
Utility of PET-MRI in Post-treatment Surveillance of Paediatric Brain Tumours: a Pilot Study
1 other identifier
interventional
5
1 country
1
Brief Summary
This is a pilot project to explore the utility of PET-MRI in the post-treatment surveillance of high-grade gliomas or medulloblastomas in children in our institution.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Feb 2024
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 21, 2022
CompletedFirst Posted
Study publicly available on registry
September 26, 2022
CompletedStudy Start
First participant enrolled
February 28, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
May 6, 2026
September 1, 2025
2.8 years
September 21, 2022
April 29, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Determine number of patients able to recruited for study in one year
Determine feasibility of recruitment for study by measuring the number of patients able to recruited for study in one year
1 year
Secondary Outcomes (2)
Acceptability
1 year
Accuracy
1 year
Study Arms (1)
Diagnostic (PET-MRI)
EXPERIMENTALPatients will undergo PET-MRI
Interventions
magnetic resonance imaging with positron emission tomography scanning using the tracer 18F-FDG
Eligibility Criteria
You may qualify if:
- Have a presumptive or histologically confirmed diagnosis of a malignant brain tumour requiring treatment
- Diagnostic uncertainty about tumour recurrence post-treatment based on conventional MR imaging in the opinion of the MDT
- Have a life expectancy of at least three months
- Able to comply with an MRI scan without a general anaesthetic
You may not qualify if:
- Unable to comply with an MRI scan without a general anaesthetic
- Diabetes or other causes of hyperglycaemia
- Pregnancy
- Patient body habitus above scanner dimensions
- Standard contra-indication to MRI (eg. pacemaker, non-compatible metallic implants, altered renal function)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Sheffieldcollaborator
- Sheffield Children's NHS Foundation Trustlead
- GE Healthcarecollaborator
Study Sites (1)
Sheffield Children's Hospital
Sheffield, South Yorkshire, S10 1SN, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ola Rominyi, MBChB
University of Sheffield
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 21, 2022
First Posted
September 26, 2022
Study Start
February 28, 2024
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
June 1, 2027
Last Updated
May 6, 2026
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share